Interestingly, residual PDX tumours had differentially activated epigenetic regulators including HDAC7, HDAC10 and SIRT7, suggesting that these epigenetic regulators can act as promising candidates for TNBC tumours with residual disease in combination with metabolic inhibitors46. Here, HDAC10 is linked to neoplasm.